Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 26;12:1629–1640. doi: 10.2147/OTT.S196713

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Gao et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

ARQ-197 enhances the antitumor effect of sorafenib or inhibits the survival of HCC cells in a dose-dependent manner.

Notes: The HCC cells MHCC97-H (A), LM-3 (B), and HepG2 (C), which were pretreated with IC₂₅ concentration of ARQ-197, were treated with indicated concentrations of sorafenib. Next, the cells were analyzed by MTT experiments. Inhibition rates of sorafenib on HCC cells were calculated at OD 490 nm.

Abbreviation: HCC, hepatocellular carcinoma.